FutureChem Co.Ltd Asset Resilience Ratio
FutureChem Co.Ltd asset resilience ratio. FutureChem Co.Ltd (220100) has an Asset Resilience Ratio of 24.16% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 220100 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of FutureChem Co.Ltd (2016–2025)
Asset resilience ratio of FutureChem Co.Ltd from 2016 to 2025. This chart shows how FutureChem Co.Ltd's Asset Resilience Ratio has changed over time. Read 220100 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down FutureChem Co.Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see FutureChem Co.Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩16.84 Billion | 24.16% |
| Total Liquid Assets | ₩16.84 Billion | 24.16% |
Asset Resilience Insights
- Good Liquidity Position: FutureChem Co.Ltd maintains a healthy 24.16% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
FutureChem Co.Ltd Industry Peers by Asset Resilience Ratio
Compare FutureChem Co.Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Sandoz Group AG
SW:SDZ |
Drug Manufacturers - Specialty & Generic | 7.89% |
|
H Lundbeck A/S
CO:HLUN-B |
Drug Manufacturers - Specialty & Generic | -0.56% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Viyash Scientific Limited
NSE:SEQUENT |
Drug Manufacturers - Specialty & Generic | 0.08% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
FutureChem Co.Ltd Asset Resilience Ratio by Year (2016–2025)
FutureChem Co.Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for FutureChem Co.Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 29.78% | ₩22.20 Billion ≈ $15.04 Million |
₩74.53 Billion ≈ $50.51 Million |
-7.06pp |
| 2024-12-31 | 36.84% | ₩27.42 Billion ≈ $18.58 Million |
₩74.42 Billion ≈ $50.43 Million |
+13.02pp |
| 2023-12-31 | 23.82% | ₩17.35 Billion ≈ $11.76 Million |
₩72.83 Billion ≈ $49.36 Million |
-18.50pp |
| 2022-12-31 | 42.31% | ₩37.54 Billion ≈ $25.44 Million |
₩88.72 Billion ≈ $60.12 Million |
+4.64pp |
| 2021-12-31 | 37.67% | ₩29.06 Billion ≈ $19.69 Million |
₩77.14 Billion ≈ $52.27 Million |
-14.26pp |
| 2020-12-31 | 51.93% | ₩42.82 Billion ≈ $29.02 Million |
₩82.46 Billion ≈ $55.88 Million |
+48.14pp |
| 2019-12-31 | 3.79% | ₩2.40 Billion ≈ $1.62 Million |
₩63.21 Billion ≈ $42.84 Million |
-55.97pp |
| 2018-12-31 | 59.76% | ₩38.28 Billion ≈ $25.94 Million |
₩64.05 Billion ≈ $43.40 Million |
+28.78pp |
| 2017-12-31 | 30.98% | ₩11.15 Billion ≈ $7.56 Million |
₩36.00 Billion ≈ $24.40 Million |
+12.86pp |
| 2016-12-31 | 18.12% | ₩6.00 Billion ≈ $4.07 Million |
₩33.11 Billion ≈ $22.44 Million |
-- |
About FutureChem Co.Ltd
FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products i… Read more